| Literature DB >> 33925700 |
Mateusz Gajda1,2, Emilia Załugowicz3, Monika Pomorska-Wesołowska4, Tomasz Bochenek5, Barbara Gryglewska6, Dorota Romaniszyn1, Agnieszka Chmielarczyk1, Jadwiga Wójkowska-Mach1.
Abstract
Infected chronic venous ulcers (VUs) represent a major health problem. We analysed the aerobic microbiome in the VUs, the virulence, and drug-resistance of Staphylococcus aureus (SA) strains. Swabs from 143 outpatients and inpatients Polish subjects were collected. SA strains were tested for drug sensitivity using a phenotyping method and for methicillin-resistant SA (MRSA) and macrolide-lincosamide-streptogramin B (MLSB) resistance using PCR. We analysed virulence genes, the genetic similarity of strains, and performed Staphylococcal cassette chromosome mec typing and Staphylococcal protein A typing. SA was isolated as a single one in 34.9% of cases, 31.5% paired with another pathogen, and 33.6% S. aureus combined with at least two other strains. The majority of SA isolates (68.5%) possessed the virulence lukE gene. Drug resistance was significantly common in hospitalised than in ambulatory patients (OR 3.8; 95%CI 1.8-7.91). MLSB (altogether in 19.6% isolates) were observed mostly in non-hospitalised patients (OR 9.1; 95%CI 1.17-71.02), while MRSA was detected in 11.9% of strains equally. Hospitalisation and patient's age group (aged > 78.0 or < 54.5 years) were significant predictors of the multi-drug resistant SA (MDR-SA). Over 30% of the infected VUs were associated with multi-species biofilms and presence of potentially highly pathogenic microorganisms. Elderly hospitalised patients with chronic venous ulcers are prone to be infected with a MDR-SA.Entities:
Keywords: Staphylococcus aureus; drug resistance; leg ulcers; virulence
Year: 2021 PMID: 33925700 PMCID: PMC8124697 DOI: 10.3390/ijerph18094662
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Microbiota isolated from infected venous ulcers from 143 patients, numbers indicate numbers of patients. Legend: EC Escherichia coli; EF Enterococcus faecalis; ENT Enterobacter spp.; GAS Streptococcus group A; GBS Streptococcus group B; MOR bacteria from Morganellaceae family; NF other non fermenting bacteria; OTH-E other bacteria from Enterobacteriaceae family; PAR Pseudomonas aeruginosa; SA Staphylococcus aureus; Y yeast. n—number of patients in the group with one, two, three or four pathogens in addition to SA in the polymicrobial group, respectively.
Other isolated pathogens.
| Identified Pathogen |
|
|---|---|
| 30 | |
| 10 | |
| 9 | |
| 19 | |
| 19 | |
|
| |
| 12 | |
| 3 | |
| 6 | |
|
| |
| 17 | |
|
| 3 |
|
| 1 |
| 15 | |
|
| |
| 13 | |
|
| 4 |
| 7 | |
Characteristics of the study group according to drug sensitivity of Staphylococcus aureus.
| Characteristics of the Study Group | Total | Sensitivity to Antibiotics | OR (95% CI) | |
|---|---|---|---|---|
| Yes | No | |||
|
| ||||
| ≤59 years | 45 (31.5) | 23 (33.3) | 22 (30.1) | 0.8 (0.36–1.73) |
| 60–75 years | 58 (40.6) | 33 (47.8) | 25 (34.2) | ref. |
| 76–80 years | 16 (11.2) | 6 (8.7) | 10 (13.7) | 0.5 (0.15–1.41) |
| ≥81 years | 24 (16.8) | 7 (10.1) | 16 (21.9) | 0.3 (0.12–0.93) |
|
| ||||
| Female | 76 (53.2) | 34 (48.6) | 42 (57.5) | 0.7 (0.36–1.35) |
| Male (ref.) | 67 (46.9) | 36 (51.4) | 31 (42.5) | |
|
| ||||
| yes | 48 (32.2) | 29 (41.4) | 19 (26.0) | 2.0 (0.99–4.08) |
| no | 95 (66.4) | 41 (58.6) | 54 (74.0) | |
|
| ||||
| surgical wards | 61 (42.7) | 26 (37.1) | 35 (47.8) | 0.9 (0.40–2.19) |
| non-surgical wards or LTCF | 34 (23.8) | 15 (21.4) | 19 (13.3) | |
|
| ||||
|
| 17 (11.9) | n/a | 17 (11.9) | n/a |
|
| 8 (5.6) | n/a | 8 (5.6) | n/a |
|
| 2 (1.4) | n/a | 2 (1.4) | n/a |
|
| 1 (0.7) | n/a | 1 (0.7) | n/a |
|
| ||||
|
| 98 (68.5) | 45 (64.3) | 53 (72.6) | 0.7 (0.33–1.38) |
|
| 17 (11.9) | 9 (12.9) | 8 (11.0) | 1.2 (0.43–3.30) |
|
| 2 (1.4) | 1 (1.4) | 1 (1.4) | 1.0 (0.06–17.01) |
|
| 23 (16.1) | 10 (14.3) | 13 (17.8) | 0.8 (0.31–1.89) |
Legend: etA/B exfoliative toxin A and/or B; LTCF long term care facilities; lukE LukDE leukocidin; n/a not applicable; OR—Odds ratio; (95%CI) 95% Confidence Interval; pvl Panton-Valentine leukocidin; ref.—reference; tsst-1 toxic shock syndrome toxin-1.
Drug-resistance of Staphylococcus aureus isolated from hospitalised and non-hospitalised patients.
| Antimicrobial Category | Antimicrobial Agent | Total | Hospital Stay | OR (95%CI) | |
|---|---|---|---|---|---|
| Yes, | No, | ||||
| Aminoglycosides | Gentamicin | 24 (16.8) | 16 (16.8) | 8 (16.7) | 0.9 (0.38–2.45) |
| Amikacin | 29 (20.2) | 19 (20.0) | 10 (20.8) | 2.1 (0.71–5.89) | |
| Tobramycin | 39 (27.3) | 27 (28.4) | 12 (25.0) | 1.1 (0.51–2.49) | |
| Anti-MRSA cephalosporins | Ceftaroline | 0 (0) | 0 (0.0) | 0 (0.0) | n/a |
| Fluoroquinolones | Ciprofloxacin | 25 (17.5) | 20 (21.1) | 5 (10.4) | 2.2 (0.76–6.26) |
| Moxifloxacin | 18 (12.6) | 14 (14.7) | 4 (8.3) | 0.5 (0.23–1.33) | |
| Folate pathway inhibitors | Trimethoprim/Sulfamethoxazole | 8 (5.6) | 6 (6/3) | 2 (4.2) | 1.5 (0.29–7.65) |
| Lincosamides | Clindamycin | 29 (20.2) | 18 (18.9) | 11 (22.9) | 0.7 (0.32–1.74) |
| Macrolides | Erythromycin | 31 (21.6) | 17 (17.9) | 14 (29.2) | 0.6 (0.27–1.43) |
| Glycopeptides | Vancomycin | 0 (0) | 0 (0.0) | 0 (0.0) | n/a |
| Glycylcyclines | Tigecycline | 0 (0) | 0 (0.0) | 0 (0.0) | n/a |
| Oxazolidinones | Linezolid | 0 (0) | 0 (0.0) | 0 (0.0) | n/a |
| Phenicols | Chloramphenicol | 16 (11.2) | 13 (13.7) | 3 (6.2) | 0.3 (0.13–0.69) |
| Streptogramins | Quinupristin-dalfopristin | 0 (0) | 0 (0.0) | 0 (0.0) | n/a |
| Tetracyclines | Tetracycline | 35 (24.5) | 27 (28.4) | 8 (16.7) | 1.9 (0.78–4.56) |
| Doxycycline | 19 (13.3) | 13 (13.7) | 6 (12.5) | 1.1 (0.37–2.99) | |
| Others (O) | Mupirocin | 8 (5.6) | 5 (5.3) | 3 (6.2) | 0.8 (0.18–3.49) |
|
| |||||
| MRSA, yes | 17 (11.9) | 12 (12.6) | 5 (10.4) | 1.2 (0.39–3.59) | |
| MLSB, yes | 28 (19.6) | 16 (16.8) | 12 (25.0) | 9.1 (1.17–71.02) | |
|
| |||||
| 0 categories (fully susceptible) | 70 (49) | 41 (43.2) | 29 (60.4) | 0.4 (0.22–0.92) | |
| 1 category | 26 (18.2) | 23 (24.2) | 3 (6.2) | 4.8 (1.38–17.06) | |
| Aminoglycosides | 9 (6.3) | 7 (7.4) | 2 (4.2) | ||
| Tetracyclines | 9 (6.3) | 9 (9.5) | 0 (0.0) | ||
| Phenicols | 4 (2.8) | 4 (4.2) | 0 (0.0) | ||
| Fluoroquinolones | 2 (1.4) | 2 (2.1) | 0 (0.0) | ||
| Lincosamides | 1 (0.7) | 1 (1.1) | 0 (0.0) | ||
| Macrolides | 1 (0.7) | 0 (0.0) | 1 (2.1) | ||
| 2 categories | 19 (13.3) | 11 (11.6) | 8 (16.7) | 0.6 (0.23–1.67) | |
| Macrolides + Lincosamides | 5 (3.5) | 2 (2.1) | 3 (6.3) | ||
| Tetracyclines + Phenicols | 3 (2.1) | 2 (2.1) | 1 (2.1) | ||
| Aminoglycosides + Fluoroquinolones | 3 (2.1) | 3 (3.2) | 0 (0.0) | ||
| Tetracyclines + Fluoroquinolones | 2 (1.4) | 2 (2.1) | 0 (0.0) | ||
| Aminoglycosides + Tetracycline | 2 (1.4) | 1 (1.1) | 1 (2.1) | ||
| Aminoglycosides A+ Phenicols | 2 (1.4) | 1 (1.1) | 1 (2.1) | ||
| Tetracyclines + Macrolides | 1 (0.7) | 0 (0.0) | 1 (2.1) | ||
| Aminoglycosides + Macrolides | 1 (0.7) | 0 (0.0) | 1 (2.1) | ||
| 3 categories or more | 28 (19.6) | 19 (20.0) | 8 (16.7) | 1.2 (0.48–2.96) | |
OR (95%CI) 95% confidence intervals of odds ratio; MRSA—methicillin resistant Staphylococcus aureus; MLSB—Macrolide-lincosamide-streptogramin B resistance phenotype.
Figure 2Analysis of the genetic similarity between S. aureus isolates by the PFGE (Pulsed-Field Gel Electrophoresis) method based on spa and sccmec genes.